Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh

Infection and Immunity

Volumn 73, Issue 10, 2005, Pages 6577-6583

  Qadri, Firdausi ^a,f   Svennerholm, Ann Mari ^b   Shamsuzzaman, Sohel ^a   Bhuiyan, Taufiqur Rahman ^a   Harris, Jason B ^c   Ghosh, A N ^d   Nair, G Balakrish ^a   Weintraub, Andrej ^e   Faruque, Shah M ^a   Ryan, Edward T ^c   Sack, David A ^a   Calderwood, Stephen B ^c  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f ICDDRB Laboratory Sciences Division   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; CHOLERA VACCINE; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; MONOCLONAL ANTIBODY; NALIDIXIC ACID; STREPTOMYCIN; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BANGLADESH; CHOLERA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; EPIDEMIC; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEMBRANE STRUCTURE; NONHUMAN; PHAGOCYTOSIS; PHASE CONTRAST MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; SERUM; VIBRIO CHOLERAE;

EID: 25444465917     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.10.6577-6583.2005     Document Type: Article

References (38)

1. Albert, M. J. 1996. Epidemiology & molecular biology of Vibrio cholerae O139 Bengal. Indian J. Med. Res. 104:14-27.
2. Albert, M. J., F. Qadri, N. A. Bhuivan, S. M. Abroad, M. Ansaruzzaman, and A. Weintraub. 1999. Phagocytosis of Vibrio cholerae O139 Bengal by human polymorphonuclear leukocytes. Clin. Diagn. Lab. Immunol. 6:276-278.
3. Albert, M. J., A. K. Siddique, M. S. Islam, A. S. Panique, M. Ansaruzzaman, S. M. Panique, and R. B. Sack. 1993. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet 341:704.
4. Attridge, S. R., F. Qadri, M. J. Albert, and P. A. Manning. 2000. Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis. Clin. Diagn. Lab. Immunol. 7:444-450.
5. Benitez, J. A., A. J. Silva, and R. A. Finkelstein. 2001. Environmental signals controlling production of hemagglutinin/protease in Vibrio cholerae. Infect. Immun. 69:6549-6553.
6. Bik, E. M., A. E. Bunschoten, R. J. Willems, A. C. Chang, and F. R. Mooi. 1996. Genetic organization and functional analysis of the otn DNA essential for cell-wall polysaccharide synthesis in Vibrio cholerae O139. Mol. Microbiol. 20:799-811.
7. Calia, K. E., M. Murtagh, M. J. Ferraro, and S. B. Calderwood. 1994. Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes. Infect. Immun. 62:1504-1506.
8. Comstock, L. E., J. A. Johnson, J. M. Michalski, J. G. Morris, Jr., and J. B. Kaper. 1996. Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol. Microbiol. 19:815-826.
9. Comstock, L. E., D. Maneval, Jr., P. Panigrahi, A. Joseph, M. M. Levine, J. B. Kaper, J. G. Morris, Jr., and J. A. Johnson. 1995. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect. Immun. 63:317-323.
10. Coster, T. S., K. P. Killeen, M. K. Waldor, D. T. Beattie, D. R. Spriggs, J. R. Kenner, A. Trofa, J. C. Sadoff, J. J. Mekalanos, and D. N. Taylor. 1995. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 345:949-952.
11. Faruque, S. M., N. Chowdhury, M. Kamruzzaman, Q. S. Ahmad, A. S. Faruque, M. A. Salam, T. Ramamurthy, G. B. Nair, A. Weintraub, and D. A. Sack. 2003. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg. Infect. Dis. 9:1116-1122.
12. Faruque, S. M., D. A. Sack, R. B. Sack, R. R. Colwell, Y. Takeda, and G. B. Nair. 2003. Emergence and evolution of Vibrio cholerae O139. Proc. Natl. Acad. Sci. USA 100:1304-1309.
13. Faruque, S. M., M. N. Saha, Asadulghani, P. K. Bag, R. K. Bhadra, S. K. Bhattacharya, R. B. Sack, Y. Takeda, and G. B. Nair. 2000. Genomic diversity among Vibrio cholerae O139 strains isolated in Bangladesh and India between 1992 and 1998. FEMS Microbiol. Lett. 184:279-284.
14. Faruque, S. M., M. N. Saha, Asadulghani, D. A. Sack, R. B. Sack, Y. Takeda, and G. B. Nair. 2000. The O139 serogroup of Vibrio cholerae comprises diverse clones of epidemic and nonepidemic strains derived from multiple V. cholerae O1 or non-O1 progenitors. J. Infect. Dis. 182:1161-1168.
15. Garg, S., A. N. Ghosh, A. K. Mukhopadhyay, and G. B. Nair. 1996. Electron microscopic studies on Vibrio cholerae O139. Indian J. Med. Res. 104:134-138.
16. Glass, R. I., A. M. Svennerholm, M. R. Khan, S. Huda, M. I. Huq, and J. Holmgren. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242.
17. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1996. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 14:1459-1465.
18. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J. Clin. Microbiol. 24:203-209.
19. Jonson, G., J. Osek, A. M. Svennerholm, and J. Holmgren. 1996. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Infect. Immun. 64:3778-3785.
20. Kaper, J. B., J. G. Morris, Jr., and M. M. Levine. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86.
21. Losonsky, G. A., Y. Lim, P. Motamedi, L. E. Comstock, J. A. Johnson, J. G. Morris, Jr., C. O. Tacket, J. B. Kaper, and M. M. Levine. 1997. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin. Diagn. Lab. Immunol. 4:264-269.
22. Matthews, K. R., B. M. Jayarao, A. J. Guidry, E. F. Erbe, W. P. Wergin, and S. P. Oliver. 1994. Encapsulation of Streptococcus uberis: influence of storage and cultural conditions. Vet. Microbiol. 39:361-367.
23. Mel, S. F., K. J. Fullner, S. Wimer-Mackin, W. I. Lencer, and J. J. Mekalanos. 2000. Association of protease activity in Vibrio cholerae vaccine strains with decreases in transcellular epithelial resistance of polarized T84 intestinal epithelial cells. Infect. Immun. 68:6487-6492.
24. Morris, J. G., Jr., G. E. Losonsky, J. A. Johnson, C. O. Tacket, J. P. Nataro, P. Panigrahi, and M. M. Levin. 1995. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J. Infect. Dis. 171:903-908.
25. Pascual, M., X. Rodo, S. P. Ellner, R. Colwell, and M. J. Bouma. 2000. Cholera dynamics and El Nino-Southern Oscillation. Science 289:1766-1769.
26. Qadri, F., T. Ahmed, M. A. Waned, F. Ahmed, N. A. Bhuiyan, A. S. Rahman, J. D. Clemens, R. E. Black, and M. J. Albert. 2004. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed. B subunit-whole cell, oral cholera vaccine. Vaccine 22:416-421.
27. Qadri, F., M. Asaduzzaman, C. Wenneras, G. Mohi, M. J. Albert, M. A. Salam, R. B. Sack, M. Jertborn, J. R. McGhee, D. A. Sack, and J. Holmgren. 2000. Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens. Infect. Immun. 68:6077-6081.
28. Qadri, F., T. R. Bhuiyan, K. K. Dutta, R. Raqib, M. S. Alam, N. H. Alam, A. M. Svennerholm, and M. M. Mathan. 2004. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 53:62-69.
29. Qadri, F., A. Chowdhury, J. Hossain, K. Chowdhury, T. Azim, T. Shimada, K. M. Islam, R. B. Sack, and M. J. Albert. 1994. Development and evaluation of rapid monoclonal antibody-based coagglutination test for direct detection of Vibrio cholerae O139 synonym Bengal in stool samples. J. Clin. Microbiol. 32:1589-1590.
30. Qadri, F., M. A. Haque, A. Hossain, T. Azim, K. Alam, and M. J. Albert. 1993. Role of Shigella dysenteriae type 1 slime polysaccharide in resistance to serum killing and phagocytosis. Microb. Pathog. 14:441-449.
31. Qadri, F., G. Mohi, J. Hossain, T. Azim, A. M. Khan, M. A. Salam, R. B. Sack, M. J. Albert, and A. M. Svennerholm. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab. Immunol. 2:685-688.
32. Qadri, F., C. Wenneras, M. J. Albert, J. Hossain, K. Mannoor, Y. A. Begum, G. Mohi, M. A. Salam, R. B. Sack, and A. M. Svennerholm. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65:3571-3576.
33. Ramamurthy, T., S. Garg, R. Sharma, S. K. Bhattacharya, G. B. Nair, T. Shimada, T. Takeda, T. Karasawa, H. Kurazano, A. Pal, et al. 1993. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 341:703-704.
34. Rodo, X., M. Pascual, G. Fuchs, and A. S. Faruque. 2002. ENSO and cholera: a nonstationary link related to climate change? Proc. Natl. Acad. Sci. USA 99:12901-12906.
35. Saha, D., R. C. LaRocque, A. I. Khan, J. B. Harris, Y. A. Begum, S. M. Akramuzzaman, A. S. Faruque, E. T. Ryan, F. Qadri, and S. B. Calderwood. 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis. 189:2318-2322.
36. Tacket, C. Ë., G. Losonsky, J. P. Nataro, L. Comstock, J. Michalski, R. Edelman, J. B. Kaper, and M. M. Levine. 1995. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J. Infect. Dis. 172:883-886.
37. Trach, D. D., P. D. Cam, N. T. Ke, M. R. Rao, D. Dinh, P. V. Hang, N. V. Hung, D. G. Canh, V. D. Thiem, A. Naficy, B. Ivanoff, A. M. Svennerholm, J. Holmgren, and J. D. Clemens. 2002. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. W. H. O. 80:2-8.
38. Waldor, M. K., R. Colwell, and J. J. Mekalanos. 1994. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc. Natl. Acad. Sci. USA 91:11388-11392.